ArticleEuropean journal of public health2025
Increasing incidence and prevalence of Hodgkin's lymphoma in Finland: a population-based registry study.
Article in European journal of public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of TNF-α, TGF-β1, IFN-γ, IL-6, and IL-10 Gene Polymorphisms with Hodgkin Lymphoma: Susceptibility and Clinical Outcomes.Journal of clinical medicine · 2026Article
- Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.HemaSphere · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Hodgkin's lymphoma (HL) is a lymphoid malignancy with an emphasized incidence in developed countries. This study aimed to assess the changes in the epidemiology of HL in Finland at the population level by utilizing data from six nationwide healthcare registries. A total of 2912 patients with HL, diagnosed and treated between 2000 and 2019 were matched by controls and divided into younger (<50 years) and older cohorts (≥50 years) for analysis. A slightly increasing trend in incidence per age group was observed. For the younger patients, the mean annual incidence was 3.19 for males and 2.89 for females. For the older patients, it was 3.07 and 1.59, respectively. Finland has higher incidence rates than other Scandinavian countries possibly due to unique human leucocyte antigen allele distribution. There was a notable increase in prevalence. For females, this was particularly emphasized between the ages of 30-50 years, while among males, it was more evenly distributed across all ages. As a result of improved disease management, the proportion of HL survivors is increasing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.